Abstract
The present research aimed to screen and evaluate the anticancer effect of Naringi crenulata phytocompounds on HER2+ human breast cancer cells. The cytotoxicity assay was performed to select effective solvent extraction. Extracted compounds showed lower toxicity on normal breast cells and significant cytotoxicity on human HER2+ breast cancer cells (SK-BR3) with an IC50 value of 24.59 μg/mL. The results indicate that the Naringi crenulata extract (NCE) shows anticancer potential via stimulating the cellular death of cancerous cells. The findings of the present study thus suggest that NCE supplementation might help in the treatment of HER2+ breast cancer.
Disclosure statement
We have no conflicts of interest to disclose.
Data availability statement
The data that support this study are available from the corresponding author upon reasonable request.